An antibody that Roche licensed from Genmab for oncology indications, pursued into Phase II, then dropped two years ago, is restarting clinical development in an ophthalmic indication.
An antibody that Roche licensed from Genmab for oncology indications, pursued into Phase II, then dropped two years ago, is restarting clinical development in an ophthalmic indication.
According to Genmab, River Vision Development Corporation has licensed RG1507 (now known as teprotumumab) from Roche and will conduct a...
Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.
A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.
Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.
